Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -124.45% is 27% below its 5-year average of -98.11%, around the middle of its 5-year range (-193.63%–0.00%).
34.18% below its 12-month average of -92.75%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -31.37%.
RETURN ON ASSETS (ROA)
-124.45%
RETURN ON ASSETS (ROA) AVG TTM
-92.75%
RETURN ON ASSETS (ROA) AVG 3Y
-98.77%
RETURN ON ASSETS (ROA) AVG 5Y
-98.11%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-34.18%
CURRENT VS 3Y AVG
-26.01%
CURRENT VS 5Y AVG
-26.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-305.37%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$554.85M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$554.42M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$554.29M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$560.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$566.81M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$542.85M
Return on Assets (ROA)
-30.29%
TTM Avg
-86.87%
3Y Avg
-85.61%
5Y Avg
-77.02%
Market Cap
$541.30M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$569.16M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$573.38M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $554.85M | -124.45% | -92.75% | -98.77% | -98.11% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $554.42M | -42.15% | -50.20% | -44.84% | -47.93% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.29M | -37.16% | -32.95% | -32.95% | -32.95% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $566.81M | 20.70% | 2.32% | -24.93% | -30.88% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.85M | -30.29% | -86.87% | -85.61% | -77.02% |
| Delcath Systems, Inc. (DCTH)vs › | $541.30M | 0.39% | -16.14% | -90.03% | -84.55% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.16M | -20.89% | 7.49% | -5.84% | -12.60% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -59.22% | -47.88% | -51.20% | -67.88% |
| ProKidney Corp. (PROK)vs › | $536.32M | -34.82% | -17.21% | -15.93% | -60.12% |
ROA
-124.5%
ROE
-306.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -83.39% |
| 2024-12-31 | -102.11% |
| 2023-12-31 | -116.03% |
| 2022-12-31 | -93.53% |
| 2021-12-31 | -193.63% |
| 2020-12-31 | 0.00% |
